- Trelagliptin
-
- $65.00
-
2026-08-25
- CAS:865759-25-7
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- Trelagliptin
-
- $56.00
-
2026-07-29
- CAS:865759-25-7
- Purity: 98.94%
- Supply Ability: 10g
- Trelagliptin
-
-
2025-04-04
- CAS:865759-25-7
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
|
| Product Name: | Trelagliptin | | Synonyms: | Trelagliptin(syr472);Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H) -pyrimidinyl]methyl]-4-fluoro-;Trelagliptin (R)-2-[[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl]-4-fluorobenzonitrile;(S)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile;Trelagliptin Isomer Impurity;Trelagliptin, >=98%;Trelagliptin free base;Trelagliptin | | CAS: | 865759-25-7 | | MF: | C18H20FN5O2 | | MW: | 357.38 | | EINECS: | 1592732-453-0 | | Product Categories: | API;Trelagliptin;Inhibitors | | Mol File: | 865759-25-7.mol |  |
| | Trelagliptin Chemical Properties |
| Boiling point | 519.0±60.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥11.6 mg/mL in DMSO; ≥3.68 mg/mL in EtOH with gentle warming and ultrasonic; ≥93.8 mg/mL in H2O | | form | solid | | pka | 9.88±0.20(Predicted) | | color | White to off-white | | InChI | InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1 | | InChIKey | IWYJYHUNXVAVAA-OAHLLOKOSA-N | | SMILES | C(#N)C1=CC=C(F)C=C1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 |
| | Trelagliptin Usage And Synthesis |
| Preparation | Using 2-bromo-5-fluorotoluene as a raw material, non-toxic potassium ferrocyanide was used as the cyanating agent, and palladium acetate was used as the catalyst to add the cyano group. Then, N-bromosuccinimide (NBS) was used as the brominating agent, and azobisisobutyronitrile (AIBN) was used as the catalytic free radical reaction. After substitution reaction, R-3-aminopiperidine was added, and then it formed a salt with TFA. Finally, it formed a salt with succinic acid in THF via salt-to-salt conversion to form trelagliptin succinate. Starting with 2-bromo-5-fluorotoluene (2) and dimethylformamide (DMF) as solvent, the mixture was heated to 165°C and coupled with cuprous cyanide to form a cyano group. The free radical reaction formed 2-bromomethyl-4-fluorobenzyl nitrile (4), which then underwent a substitution reaction with 3-methyl-6-chlorouracil to generate 2-(6-chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-4-fluorobenzyl nitrile (5). This 5-fluorobenzyl nitrile then reacted with R-3-aminopiperidine dihydrochloride and trifluoroacetic acid (TFA) in ethanol to form the trifluoroacetate salt of the target product, trelagliptin. | | Uses | Trelagliptin is a highly selective, long-acting dipeptidyl peptidase IV (DPP-4) inhibitor. This inhibitor provides sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. | | Definition | ChEBI: Trelagliptin is a member of benzenes and a nitrile. | | Biological Activity | trelagliptin (syr-472) is a selective inhibitor of dpp-4 and is developed for the treatment of type 2 diabetes mellitus (t2dm) [1].dipeptidyl peptidase (dpp)-4 also known as adenosine deaminase complexing protein 2 or cd26 is an antigenic enzyme that expressed on the surface of most cell types and plays an important role in regulating immune system, signal transduction and apoptosis [2, 3].trelagliptin (syr-472) is a potent dpp-4 inhibitor and can be administered once weekly which unlike its other class approved agents that be taken once daily [1]. in japan, | | in vivo | Trelagliptin (oral gavage; 7 mg/kg; single dose) shows sustained PD effect in dogs and gives >80% inhibition of DPP-4 activity even after 24h[1].Trelagliptin (oral gavage; 3 mg/kg; single dose; 60 min prior to oral glucose) significantly improves the glucose tolerance capacity by decreasing the AUC0120min of 19.3% compared with the vehicle group in ob/ob mice[3].
Trelagliptin (oral gavage; 10 mg/kg; once a week; 8 weeks) caused significant reductions in fasting blood glucose (FBG) levels, and the average reduction during the entire treatment period is 16.8% compared to the control.It also increases insulin level and raised it by 1.7-fold
in AUC0120min in ob/ob mice[3]. | Animal Model: | ICR ob/ob mice[3] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; 10 mg/kg; once a week; 8 weeks | | Result: | Exerted chronic antidiabetic effects on type 2 diabetic db/db Mice.
|
| | target | DPP-4 | | IC 50 | DPP-4 | | references | [1]. mckeage, k., trelagliptin: first global approval. drugs, 2015. 75(10): p. 1161-4.
[2]. inagaki, n., et al., once-weekly trelagliptin versus daily alogliptin in japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. lancet diabetes endocrinol, 2015. 3(3): p. 191-7.
[3]. inagaki, n., et al., syr-472, a novel once-weekly dipeptidyl peptidase-4 (dpp-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. lancet diabetes endocrinol, 2014. 2(2): p. 125-32. |
| | Trelagliptin Preparation Products And Raw materials |
|